️ Episode 132: Tumor transcriptome classifiers predict treatment sensitivity in advanced prostate cancer

In this episode of PaperCast Base by Base, we explore how transcriptome-wide RNA expression classifiers from advanced prostate cancers can inform treatment selection and improve patient outcomes.

Study Highlights:
Researchers analyzed tumor transcriptome profiles and immunohistochemistry markers from 1,523 patients enrolled in landmark phase 3 trials with up to 14 years of survival follow-up. High androgen receptor signaling was associated with longer survival, while increased proliferation predicted shorter survival. The Decipher classifier was both prognostic and predictive, identifying metastatic patients who benefited significantly from docetaxel. Additionally, a transcriptome classifier of PTEN inactivation revealed poor survival on hormone therapy but sensitivity to docetaxel. These findings establish transcriptome classifiers as valuable tools for guiding personalized treatment strategies.

Conclusion:
Transcriptome-wide classifiers can predict which patients with advanced prostate cancer will benefit most from docetaxel, paving the way for precision oncology approaches in routine practice.

Reference:
Grist, E., Dutey-Magni, P., Parry, M.A., Mendes, L., Sachdeva, A., Proudfoot, J.A., Hamid, A.A., Ismail, M., Howlett, S., Friedrich, S., et al. Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers. Cell. 188, 1–18 (2025). https://doi.org/10.1016/j.cell.2025.07.042

License:
This episode is based on an open-access article published under the Creative Commons Attribution 4.0 International License (CC BY 4.0) – https://creativecommons.org/licenses/by/4.0/

Support:
If you'd like to support Base by Base, you can make a one-time or monthly donation here: https://basebybase.castos.com/